Failure to follow this rule will result in cancellation of your appointment
By Patricia Van Arnum, Editorial Director, DCAT, [email protected] Whats next Glucagon-like peptide 1 (GLP-1) agonists, used to treat Type 2 diabetes and obesity, have been a success story in the industry, with Novo Nordisk riding a blockbuster wave with Ozempic/Wegovy (semaglutide), respectively for treating Type 2 diabetes and obesity, and Eli Lilly and Company also riding the wave with Mounjaro/Zepbound (tirzepatide), a dual-activating GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 medication, respectively for treating Type 2 diabetes and obesity
Although they share a common origin in the melanocortin system, they still differ in several aspects
Cell 110:673687 Danen EH, Sonnenberg A (2003) Integrins in regulation of tissue development and function
GLP-1 meds sale overall dwarfed that of Ketruda by 2:1.